Screener
SELLAS Life Sciences Group, Inc. SLS Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001390478-26-000008
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | $5,129 | $3,205 |
| General and administrative | 4,123 | 2,858 |
| Total operating expenses | 9,252 | 6,063 |
| Loss from operations | (9,252) | (6,063) |
| Non-operating income: | ||
| Interest income | 845 | 250 |
| Total non-operating income | 845 | 250 |
| Net loss | $(8,407) | $(5,813) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is SELLAS Life Sciences Group, Inc.'s operating income?
- SELLAS Life Sciences Group, Inc. (SLS) reported operating income of -$9.25M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s operating income changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s operating income decreased by 52.6% year-over-year, from -$6.06M to -$9.25M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s operating income?
- Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s operating income has grown at a 2.8% compound annual growth rate (CAGR), from -$25.29M to -$28.27M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about SELLAS Life Sciences Group, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude